Fundraising Fox

KSQ Therapeutics

Cambridge, US · Founded 2015 · Delaware corporation · 7 known investors

ksqtx.com ↗

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical Devicesin /10414448@KSQ_TX

Founders & leadership

GG
GEORGE GOLUMBESKIDirector
RA
RICHARD A. MOSCICKI, PH.D.Director
AL
ALAN L. CRANEDirector
JG
JAMES GILBERTDirector
JT
JOHN TRZUPEK, PH.D.TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER
DP
DAVID P. MEEKER, M.D.PRESIDENT AND CHIEF EXECUTIVE OFFICER
FS
FRANK STEGMEIER, PH.D.CHIEF SCIENTIFIC OFFICER
DA
DAVID A. BERRY, M.D., PH.D.Director
TW
Tim WangCofounder30 Under 30 2017

Investors · 7

Alpha Wave GlobalMiami
ARCH Venture PartnersChicago · $50K – $250M
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
Baillie GiffordreportedEdinburgh
Flagship PioneeringreportedCambridge · $500K – $10M
Polaris PartnersreportedBoston · $500K – $5M

Reported raises · per SEC filings

Form D private placements
▶$80.6MraisedOct 2018 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • GEORGE GOLUMBESKIDirector
  • RICHARD A. MOSCICKI, PH.D.Director
  • ALAN L. CRANEDirector
  • JAMES GILBERTDirector
  • JOHN TRZUPEK, PH.D.Executive Officer
  • DAVID P. MEEKER, M.D.Executive Officer, Director
  • FRANK STEGMEIER, PH.D.Executive Officer
  • DAVID A. BERRY, M.D., PH.D.Director
Offering amount
$80.6M
Amount sold
$80.6M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news